Is anti-Müllerian hormone a marker of acute cyclophosphamide-induced ovarian follicular destruction in mice pretreated with cetrorelix?

Browne, Hyacinth; Moon, K.S.; DeCherney, Alan H.; Segars, James H.; Armstrong, Alicia

doi:10.1016/j.fertnstert.2011.04.008

Cited by 14 publications

(25 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, human studies have shown that AMH directly correlates with the number of antral follicles assessed by ultrasound [5] and FSH, inhibin-B and estradiol [11]. Despite these results in human studies, serum AMH was found to have no correlation with the extent of germ cell destruction (primordial follicles) in the post-pubertal mouse when measured 10 days after CTX administration [2].…”

Section: Introductionmentioning

confidence: 90%

Serum markers of ovarian reserve and ovarian histology in adult mice treated with cyclophosphamide in pre-pubertal age

Detti

Uhlmann

Lu³

et al. 2013

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose AMH is used to quantify the extent of follicular pool in postpubertal women, but its value after chemotherapy is unclear. We tested AMH as a marker of follicular reserve in adult mice treated with cyclophosphamide (CTX) in prepubertal age. Methods Mice received placebo or CTX at age 18 days. AMH and FSH were assessed on day 43, 56, and 95 of life. Ovaries were fixed in formalin, embedded in paraffin, and stained with H&E and TUNEL. Follicular apoptosis was graded. Results All mice exposed to CTX had a decreased number of follicles/mm 2 and significantly decreased AMH, but only 48 % of pubertal and 81 % of adult mice had increased FSH. Over time, there was an increase in FSH (p <0.05), but not a concurrent decrease in AMH, while in controls, FSH remained stable and AMH decreased. There was no correlation between histological and serological markers.Conclusions CTX administration to pre-pubertal mice caused various degrees of residual function, which were reflected by FSH, but not by AMH or by the number of ovarian follicles. AMH served as a marker of quantitative, and FSH of qualitative, residual ovarian function.

show abstract

Section: Introductionmentioning

confidence: 90%

Serum markers of ovarian reserve and ovarian histology in adult mice treated with cyclophosphamide in pre-pubertal age

Detti

Uhlmann

Lu³

et al. 2013

J Assist Reprod Genet

View full text Add to dashboard Cite

show abstract

“…The dosage of cyclophosphamide was decided based on previously published literature. [18][19][20][21][22] Furthermore, cyclophosphamide was injected three times because the aim of this study was to prevent serious dysfunction of the ovary. The dosage of testosterone was also decided based on previously published reports, 23 and the serum testosterone level of mice that received testosterone (4 mg/kg) injection four times (days 1, 4, 7 and 10) was 1.04 (0.51-1.11) ng/mL.…”

Section: Animal Studymentioning

confidence: 99%

<p>The Protective Effect of Testosterone on the Ovarian Reserve During Cyclophosphamide Treatment</p>

Yoo¹,

Tanaka

Konishi³

et al. 2020

OTT

View full text Add to dashboard Cite

Introduction: Cyclophosphamide, which is widely used to treat malignant disease, causes ovarian follicular atresia, which leads to premature ovarian insufficiency. The present study evaluated the protective effect of testosterone in preventing the decline in the ovarian reserve during cyclophosphamide treatment. Methods: Using the COV434 human granulosa cell line, the protective effect of testosterone against cyclophosphamide was evaluated by immunocytochemistry, Western blotting and an MTS assay. The follicles in mouse ovaries and serum anti-Mullerian hormone were also assessed to evaluate the effects of testosterone. Results: Testosterone suppressed the decrease in cell viability and apoptosis caused by cyclophosphamide treatment in vitro. In vivo, the number of atretic follicles in the mouse ovary was significantly lower in the testosterone plus cyclophosphamide group than in the cyclophosphamide alone group (p=0.03). The serum anti-Mullerian hormone was significantly higher in the testosterone plus cyclophosphamide group than in the cyclophosphamide alone group (16.2 [9.7-22.6]) vs 11.2 [8.9-12.1], p<0.01). The rate of cleaved Caspase-3 expression in the testosterone plus cyclophosphamide group was lower than that in the cyclophosphamide alone group (28.4% vs 48.6%, p=0.03). Conclusion: These findings indicated that testosterone has the potential to prevent ovarian damage induced by cyclophosphamide by protecting granulosa cells from cyclophosphamide-induced apoptosis.

show abstract

“…A recent murine study tried to elucidate the mechanism by which the GnRH-antagonist cetrorelix acetate would protect from primordial and primary follicle depletion [32]. The authors showed a possible reduction in DNA damage when cetrorelix acetate was administered simultaneously to cyclophosphamide treatment in adult mice.…”

Section: Ovarian Suppressionmentioning

confidence: 99%

Applicability of adult techniques for ovarian preservation to childhood cancer patients

Detti

Williams

2012

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose To appraise the feasibility of current adult medical and surgical techniques for ovarian preservation in prepubertal and adolescent girls with cancer. Methods Literature search using PubMed and SCOPUS up to February 2012. In addition, the reference lists of selected studies and all identified systematic and narrative reviews were scanned for relevant references. Inclusion criteria were ovarian preservation and cancer. Exclusion criteria were non-English publications, letters, personal communications, and ovarian preservation for conditions other than cancer. Results Data from the selected publications was interpreted and discussed in the relevant sections. Cryopreservation of ovarian tissue followed by autologous transplant represents the only surgical option available for pre-pubertal girls and adolescents who cannot delay the start of chemotherapy. Few studies report on pre-pubertal and adolescent girls undergoing ovarian preservation surgeries with good harvesting, and no follow-up has been conveyed, to date. Outcomes of ovarian function after ovarian suppression with GnRH-analogs in adults have been controversial and no reports are available for pre-pubertal girls. Conclusions Autologous transplantation of cryopreserved ovarian cortex probably represents the best option for preservation of fertility and hormonal function in childhood cancer females; however, future research needs to address the safety of this technique, especially in patients with blood-borne cancers. Ovarian suppression with GnRHanalogs at the time of chemotherapy treatment has not proven to be superior to non-suppression for fertility preservation purposes in adults. Not enough evidence is presently available in childhood cancer patients.

show abstract

Is anti-Müllerian hormone a marker of acute cyclophosphamide-induced ovarian follicular destruction in mice pretreated with cetrorelix?

Cited by 14 publications

References 35 publications

Serum markers of ovarian reserve and ovarian histology in adult mice treated with cyclophosphamide in pre-pubertal age

Serum markers of ovarian reserve and ovarian histology in adult mice treated with cyclophosphamide in pre-pubertal age

<p>The Protective Effect of Testosterone on the Ovarian Reserve During Cyclophosphamide Treatment</p>

Applicability of adult techniques for ovarian preservation to childhood cancer patients

Contact Info

Product

Resources

About